ICICI Prudential Life Insurance Q2 Results: Profit rises marginally to Rs 252 crore
ICICI Prudential Life Insurance Company on Tuesday reported a marginal rise of 3 per cent in its net profit to Rs 252 crore in the September quarter. The company's net profit stood at Rs 244 crore in the same quarter a year ago.
· The Economic TimesICICI Prudential Life Insurance Company on Tuesday reported a marginal rise of 3 per cent in its net profit to Rs 252 crore in the September quarter. The company's net profit stood at Rs 244 crore in the same quarter a year ago.
Total income rose to Rs 25,229 crore from Rs 17,436 crore in the year-ago period, ICICI Prudential Life Insurance said in a regulatory filing.
The net premium earned by the private sector insurer during July-September grew to Rs 10,754 crore against Rs 10,022 crore in FY24, it said.
Its assets under management climbed 18 per cent to Rs 3,20,491 crore compared to Rs 2,44,279 crore as of September 30, 2023.
The solvency ratio was 188.6 per cent at the end of September against the regulatory requirement of 150 per cent, it said.
Stock Trading
Options Scalping Made Easy
By - Sivakumar Jayachandran, Ace Scalper
View ProgramStock Trading
Dow Theory Made Easy
By - Vishal Mehta, Independent Systematic Trader
View ProgramStock Trading
Options Trading Course For Beginners
By - Chetan Panchamia, Options Trader
View Program
However, the Value of New Business (VNB), a key measure of profitability, increased to Rs 1,058 crore over Rs 1,015 crore at the end of the second quarter of the previous fiscal.
Embedded Value grew 19.4 per cent to Rs 46,018 crore on September 30, 2024, from Rs 38,529 crore on September 30, 2023, it added.
The board of the insurance company also approved the issuance of up to Rs 1,400 crore via Non-Convertible Debentures (NCDs).
The fund would be raised in one or more tranches over the next 12 months for cash, it said.
(You can now subscribe to our ETMarkets WhatsApp channel)
...moreless
(You can now subscribe to our ETMarkets WhatsApp channel)
...moreless
Prime ExclusivesInvestment IdeasStock Report PlusePaperWealth Edition
How fake drugs, Jan Aushadhi push are eating away the profits of top pharma companies
With 100% grey market premium, India’s solar powerhouse gears up for listing gains
What Sachin Bansal must learn from Aditya Puri and Uday Kotak
10 multicap funds that have returned nearly 50% in just a year
Why a China bull run can trigger a broader emerging markets rally
- 1
- 2
- 3